3.3
CiteScore
41 days
Time to First Decision

Journal of Market Access & Health Policy, Volume 13, Issue 2

2025 June - 21 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (21)

Select all

Article

2 Citations

3,281 Views

18 Pages

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK

Nichola Cooper,
Sebastian Guterres,
Michał Pochopień,
Koo Wilson,
Sam James,
Mondher Toumi,
Anna Tytuła,
Carly Rich and
Daniel Eriksson

J. Mark. Access Health Policy2025, 13(2), 11;https://doi.org/10.3390/jmahp13020011

24 March 2025

Background: Thrombopoietin receptor agonists—romiplostim, eltrombopag and avatrombopag—are commonly used as second-line treatments for immune thrombocytopenia (ITP). Methods: A Markov model was developed to estimate the cost effectiveness...

Full Article

of 3

Get Alerted

Add your email address to receive forthcoming issues of this journal.

J. Mark. Access Health Policy - ISSN 2001-6689

Imprint

Download Flyer